Index Pharmaceuticals Ab
InDex Pharmaceuticals in brief InDex is a pharmaceutical development company focusing on immunological diseases where there is a high unmet medical need for new treatment options. The company’s lead asset is the drug candidate cobitolimod, which is being evaluated in the phase study CONCLUDE as a novel treatment of moderate to severe ulcerative colitis – a debilitating, chronic inflammation of the large intestine. InDex has also developed a platform of patent protected discovery stage substances, so called DNA based ImmunoModulatory Sequences (DIMS), with the potential to be used in the treatment of various immunological diseases. InDex is based in Stockholm, Sweden. The company’s shares (ticker INDEX) are traded on Nasdaq First North Growth Market Stockholm.
7-day free trial · no credit card
Verified contacts
10
available on Kipplo
LinkedIn employees
10
11 to 50 range
Open roles
—
no listings
Distinct roles
9
indexed titles
Tech stack
0
tools in use
Monthly traffic
—
organic / mo
Sign up free to see all 10 verified contacts at Index Pharmaceuticals Ab
Free for 7 days · 50 credits · no card · only pay for verified records.
Decision-makers and verified team members
10 contacts with verified email or phone · masked until revealed.
No verified contacts on record for this company yet.
Top roles at Index Pharmaceuticals Ab
9 distinct titles indexed · top 9 shown.
- 2pharmacist
- 1chief scientific officer diagnostics
- 1consultant
- 1director cmc
- 1head of ip and director research at index pharmaceuticals ab
- 1index pharma
- 1manager
- 1medical student at lund university
- 1sales manager
Sign up to unlock all 10 contacts at Index Pharmaceuticals Ab
Free for 7 days · 50 credits · no card · only pay for verified records.
Sign up to reveal 10 verified contacts at Index Pharmaceuticals Ab
7-day trial · no credit card · cancel anytime · only pay for verified records.
Trusted by sales, marketing, and GTM engineering teams.